文献速递泌尿生殖与妇科肿瘤放疗

IVB期宫颈癌放疗结局的系统综述与荟萃分析

Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-04-23

2年、3年、5年无病生存率分别为41.5%、34.2%、30.9%,总生存率分别为56.0%、45.9%、34.8%,膀胱阴道或直肠阴道瘘发生率为23.7%。同步放化疗和完成近距离放疗与改善结局相关。

要点

  • IVB期宫颈癌根治性放疗后5年总生存率34.8%,无病生存率30.9%。
  • 膀胱阴道或直肠阴道瘘 pooled 发生率为23.7%。
  • 同步放化疗和完成近距离放疗与改善结局相关。

核心结论

  • 尽管采用根治性治疗,IVB期宫颈癌长期生存仍较差且治疗相关并发症显著。
  • 持续盆腔控制是主要治疗挑战。
  • 同步放化疗联合足量近距离放疗似乎是获得最佳结局的关键。

研究设计与样本

  • 遵循PRISMA 2020指南和PROSPERO注册(CRD42024602426)的系统综述与荟萃分析。

主要发现

  • 2年、3年、5年无病生存率分别为41.5%(95% CI,28.1-55.0)、34.2%(95% CI,21.1-47.3)、30.9%(95% CI,16.0-45.8)。
  • 2年、3年、5年总生存率分别为56.0%(95% CI,46.2-65.9)、45.9%(95% CI,35.9-55.9)、34.8%(95% CI,26.4-43.3)。
  • 加权中位无病生存期和总生存期分别为15.6个月和33.6个月。
  • 膀胱阴道或直肠阴道瘘的合并发生率为23.7%(95% CI,12.9-34.6)。
  • 不良预后因素包括盆腔淋巴结受累、肾积水、直肠侵犯、未行近距离放疗和总EQD2低于80-85 Gy。

关键数值与推荐

  • 同步放化疗和完成近距离放疗与改善结局一致相关。

临床怎么用

  • 对IVB期宫颈癌患者,应考虑同步放化疗联合足量近距离放疗以优化结局。
  • 需关注盆腔淋巴结受累、肾积水、直肠侵犯等不良预后因素。
  • 应确保总EQD2达到80-85 Gy以上并完成近距离放疗。

局限性

  • 证据质量有限,需未来针对IVB期的专门研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

FIGO stage IVA cervical cancer, defined by bladder or rectal mucosal invasion without distant metastasis, is an uncommon but clinically challenging disease with limited high-quality evidence to guide management. We performed a systematic review and meta-analysis to evaluate survival outcomes, treatment-related morbidity, and prognostic factors in patients with stage IVA cervical cancer treated with definitive radiotherapy. Following PRISMA 2020 guidelines and PROSPERO registration (CRD42024602426), PubMed, Embase, and Web of Science were searched through February 2025. Eleven studies comprising 492 patients met eligibility criteria. Pooled random-effects analyses demonstrated 2-, 3-, and 5-year disease-free survival rates of 41.5% (95% CI, 28.1-55.0), 34.2% (95% CI, 21.1-47.3), and 30.9% (95% CI, 16.0-45.8), respectively. Corresponding overall survival rates were 56.0% (95% CI, 46.2-65.9), 45.9% (95% CI, 35.9-55.9), and 34.8% (95% CI, 26.4-43.3). Weighted median disease-free survival and overall survival were 15.6 and 33.6 months, respectively. The pooled incidence of vesicovaginal or rectovaginal fistula was 23.7% (95% CI, 12.9-34.6). Adverse prognostic factors included pelvic nodal involvement, hydronephrosis, rectal invasion, omission of brachytherapy, and total EQD2 below 80-85 Gy. Concurrent chemoradiation and completion of brachytherapy were consistently associated with improved outcomes. Despite curative-intent treatment, long-term survival remains poor and treatment-related morbidity substantial. Durable pelvic control remains the principal therapeutic challenge. Concurrent chemoradiation with adequate-dose brachytherapy appears essential for optimal outcomes, while future stage IVA-specific studies incorporating image-guided adaptive brachytherapy, advanced radiotherapy techniques, and systemic treatment intensification are needed to improve survival and reduce treatment-related morbidity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Saini SK, Srivastava S, Goel A, et al. Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2026. PMID: 42034194. doi:10.1016/j.ijrobp.2026.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。